Evidence map›Paper›PMID 37363442›Full record

ReviewTherapeutic advances in infectious disease

From sea to shining IV: the current state of OPAT in the United States.

Jeffrey Larnard, Kyleen Swords, Dan Taupin, Simi Padival

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jeffrey LarnardDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID https://orcid.org/0009-0004-1971-2961
Kyleen SwordsDivision of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Dan TaupinDivision of Infectious Diseases, Jefferson Health, Philadelphia, PA, USA.
Simi PadivalDivision of Infectious Diseases, University of Pittsburgh Medical Center Health System, Pittsburgh, PA, USA.
Beth Israel Deaconess Medical Center · USThomas Jefferson University Hospital · USUPMC Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

First described in the United States, outpatient parenteral antibiotic therapy (OPAT) has become an indispensable part of treating serious infections. The proportion of infectious disease (ID) physicians utilizing a formal OPAT program has increased in recent years, but remains a minority. In addition, many ID physicians have indicated that OPAT programs have inadequate financial and administrative support. Given the medical complexity of patients receiving OPAT, as well as the challenges of communicating with OPAT providers across health care facilities and systems, OPAT programs ideally should involve a multidisciplinary team. The majority of patients in the United States receive OPAT either at home with assistance from home infusion companies and visiting nurses or at a skilled nursing facility (SNF), though the latter has been associated with lower rates of patient satisfaction. Current and future opportunities and challenges for OPAT programs include providing OPAT services for people who inject drugs (PWID) and incorporating the increasing use of oral antibiotics for infections historically treated with parenteral therapy. In this review, we will discuss the current practice patterns and patient experiences with OPAT in the United States, as well as identify future challenges and opportunities for OPAT programs.

Indexed as

antibioticOPAToutpatientparenteraltherapyUnited StatesUSA

Identifiers

PMID37363442
PMCPMC10285263
OpenAlexW4381248717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.